Staidson Hongkong Investment Company

Staidson Hongkong Investment Company primarily operates as a strategic investment vehicle for Staidson (Beijing) Biopharmaceuticals Co., Ltd., an innovative biopharmaceutical enterprise. The core group specializes in the research, development, production, and sale of therapeutic drugs, encompassing biological products and various chemicals. Their technical approach centers on addressing unmet clinical treatment needs, notably through the development of advanced pharmaceutical solutions such as injectable mouse nerve growth factor.

Staidson (Beijing) Biopharmaceuticals Co., Ltd. was established on August 16, 2002. The company originated from an understanding of the critical necessity for advanced biopharmaceutical interventions. It quickly grew into a national high-tech enterprise, headquartered in Beijing, dedicated to pioneering scientific research and product development within the life sciences sector.

The biopharmaceutical products and therapies developed by the Staidson group serve patients in need of specialized medical treatments. The company's vision is to significantly enhance global healthcare by continuously innovating and delivering effective therapeutic agents. They aim to contribute to medical progress and improve patient well-being through ongoing scientific discovery and strategic, impactful investments.